biomarker development

AcuraStem is a patient-based biotechnology company pioneering treatments for neurodegenerative diseases including sporadic ALS and FTD. It uses its proprietary disease-modeling platform iNeuroRx® to generate individual patient models that recapitulate neurodegenerative disease processes, aiming to discover novel, effective and broadly-acting treatments. The company has a growing pipeline of antisense oligonucleotide (ASO) treatments, including lead clinical candidate AS-241.

AIantisense oligonucleotide (ASO) therapeuticsBioinformaticsdisease modelingdrug discoverytranslational science

Adora Tech L.L.C. develops AI/ML-driven platforms for early detection and prevention of life-threatening diseases, including GI cancers, lung cancers, PTSD, and Alzheimer's disease. The company integrates artificial intelligence, machine learning, and scientific research into disease screening platforms, collaborating with research and clinical institutions and focusing on regulatory compliance and patient outcomes.

AI/ML platform developmentclinical data integrationgut microbiome sequencingmachine learning modelingmetabolomicssoftware engineering for clinical integration

AdvantiGen Biosciences is expanding the landscape of Immuno-Oncology by unveiling sialic-acid-binding immunoglobulin-like lectin 5 (Siglec-5) as a novel target on activated T-cells for cancer immunotherapy. The company capitalizes on its expertise in monoclonal antibodies (mAbs) and NIRID (Near InfraRed Identification and Detection) to develop therapeutics and complementary biomarkers for pre-clinical and clinical patient selection and stratification.

immuno-oncology researchmonoclonal antibody developmentNear InfraRed Identification and Detection (NIRID)

Aqualung Therapeutics is a clinical stage immunotherapeutics company developing targeted therapies for inflammatory injury, fibrosis, and vascular leak. Its eNamptor platform includes ALT-100, a humanized monoclonal antibody designed to neutralize eNAMPT, along with complementary biomarker tools to support precision guided treatment.

clinical developmenttherapeutic developmenttranslational research

Bectas Therapeutics is a preclinical-stage biotech company developing monoclonal antibody therapies for cancer, accompanied by biomarkers to identify patients who will most benefit from each therapeutic antibody. Its programs combine monoclonal antibodies targeting secondary immune checkpoints that regulate myeloid-dependent immune suppression with patient-selection biomarkers based on insights from human patients. The company was awarded a $2.75M product development seed grant from the Cancer Prevention Research Institute of Texas (CPRIT) to support pre

monoclonal antibody developmentprecision oncologypre-clinical development

BrainScope is a neurotechnology company with over 15 years of experience that transforms brain electrical activity (EEG) into objective diagnostic insights. It developed the first FDA-cleared AI/machine learning medical device in neurology, a point-of-care technology that assesses head-injured patients for both brain bleeds and concussions. The company holds 83 issued patents and has commercialized three biomarkers for head injury assessment with 10 regulatory clearances.

artifact removalcloud/API EEG integrationcomputational neurosciencedeep learningEEG signal processingmachine learning

Cantargia AB is a Swedish listed biotechnology company that develops antibody-based therapies targeting the IL1RAP molecule for the treatment of cancer as well as inflammatory and autoimmune diseases. The company has brought two candidate drugs into clinical development, nadunolimab (CAN04) and CAN10, and develops a preclinical project CAN14 derived from its CANxx antibody platform. Cantargia was founded in 2010 by researchers Thoas Fioretos, Marcus Järås and Kjell Sjöström based on research from Lund University, and is listed on Nasdaq Stockholm's Main

antibody-based drug developmentclinical developmentcombination therapiesimmunotherapypreclinical research

CIAN, Inc. is a Delaware-incorporated start-up company founded by Professor Ramchandran in March 2023 and based in Wisconsin. It develops biomarkers based on ciliary proteins found in blood to inform changes in blood flow associated with disease, aiming for point-of-care testing that diagnoses disease severity and prognosticates outcomes. The technology stems from research at the Medical College of Wisconsin on cilia loss from endothelial cells under turbulent flow (deciliation).

diagnostics developmentresearch on cilia in brain blood vessel developmenttherapeutic development

Deliberate AI develops ambient multimodal AI for mental health, leveraging behavioral signal processing across modalities such as head and body motion, facial expressions, vocal acoustics, speech behaviors, vital signs, and oculometry/pupillometry. Its products support clinicians and researchers with assessments, treatment analysis, and documentation, and include biomarker research for CNS clinical trials.

AI-generated clinical notesambient symptom trackingbehavioral signal processingmental health screening and triagemultimodal AI

Fulcrum Neuroscience develops a proprietary mathematical model of brain metabolism and a homeostasis-first, mechanism-first modeling platform for AI drug discovery in neurodegeneration. The platform generates virtual populations of tens of millions of discrete trajectories and has produced a unified hypothesis of Alzheimer's Disease implicating cholesterol debris processing upstream of amyloid and tau. The company is developing proprietary Alzheimer's therapeutics and biomarkers and assists partners by modeling disease progression, therapeutic effects, b

AI softwarecausal homeostatic modelingclinical trial modelingdifferential equation modeling across molecular, cellular, tissue and population scalesquantitative systems pharmacologysystems biologyvirtual population generation